Antibody profile in systemic sclerosis patients: A cross-sectional study from Kashmir Valley of India

Tasleem Arif, Mohammad Adil, Iffat Hassan


Objective This study aimed to find the prevalence of the most common antibodies in patients of systemic sclerosis and to ascertain their prevalence with the limited and diffuse cutaneous variants of systemic sclerosis.


Methods Thirty-four patients of systemic sclerosis, attending the dermatology department, diagnosed as per the American Rheumatology Association criteria were recruited for this cross-sectional study. They were classified as having limited and diffuse systemic sclerosis. All patients were subjected to serum estimations of antinuclear antibodies, anticentromere antibodies and anti-Scl70 antibodies. The results were tabulated and analyzed for possible association between disease subsets and antibodies.


Results There were 27 patients with limited disease and 7 with diffuse disease. Antinuclear antibodies were seen in 76.5% of all patients. Anticentromere antibodies were seen in 9 (33.3%) limited disease patients and 1 (14.3%) in diffuse variant. The total prevalence of anticentromere antibodies was 29.4%. Anti-Scl70 antibodies were found in 5 (18.6%) and 3 (42.9%) patients of limited and diffuse disease subset, respectively. Overall, these antibodies were seen in 23.5% patients.


Conclusion Anticentromere antibodies are more common in limited systemic sclerosis while anti-Scl70 antibodies are seen more frequently in diffuse systemic sclerosis. Thus, these antibodies can act as a marker of future disease activity, severity of disease and prognosis.



Anti-centromere antibody, antinuclear antibody, anti-Scl70 antibody, systemic sclerosis

Full Text:




Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.

Barnes J, Mayes MD. Epidemiology of systemic sclerosis: incidence, prevalence, survival, risk factors, malignancy and environmental triggers. Curr Opin Rheumatol 2012;24:165-70.

Orteu CH, Denton CP. Systemic Sclerosis. In: Griffiths CEM, Barker J, Bleiker T, Chalmers R, Creamer D, editors. Rook’s textbook of dermatology. 9th ed. West Sussex (UK);Wiley Blackwell: 2016.p.56.1-23.

Arif T, Masood Q, Singh J, Hassan I. Assessment of esophageal involvement in systemic sclerosis and morphea (localized scleroderma) by clinical, endoscopic, manometric and pH metric features: a prospective comparative hospital based study. BMC Gastroenterol 2015;15:24.

Lafyatis R, York M. Innate immunity and inflammation insystemic sclerosis. Curr Opin Rheumatol 2009;21:617-22.

Kraaij MD, Van Laar JM. The role of B cells in systemicsclerosis. Biologics 2008;2:389-95.

Graf SW, Hakendorf P, Lester S, Patterson K, Walker JG, Smith MD, et al. South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome. Int J Rheum Dis 2012;15:102-9.

Hasegawa M. Biomarkers in systemic sclerosis: Their potential to predict clinical courses. J Dermatol 2016;43:29-38.

Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980;23:58-90.

Chifflot H, Fautrel B, Sordet C, Chatelus E, Sibilia J. Incidence and prevalence of systemic sclerosis: a systematic literature review. Semin Arthritis Rheum 2008;37:223-35.

Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-8.

Ruangjutipopan S, Kasitanon N, Louthrenoo W, Sukitawut W, Wichainun R. Causes of death and poor survival prognostic factors in Thai patients with systemic sclerosis. J Med Assoc Thai 2002;85:1204-9.

Sharma VK, Trilokraj T, Khaitan BK, Krishna SM. Profile of systemic sclerosis in a tertiary care center in North India. Indian J Dermatol Venereol Leprol 2006;72:416-20.

Lahcene M, Oumnia N, Matougui N, Boudjella M, Tebaibia A, Touchene B. Esophageal involvement in scleroderma: Clinical, Endoscopic, and Manometric Features. ISRN Rheumatol 2011;2011:1-5. Article id: 325826. doi:10.5402/2011/325826.

Arias Nunez M, Llorca J, Vazquez-Rodriguez TR, Gomez-Acebo I, Miranda-Filloy JA, Martin J, et al. Systemic sclerosis in northwestern Spain: a 19 year epidemiologic study. Medicine 2008;87:272-80.

Schneeberger D, Tyndall A, Kay J, Sondergaard KH, Carriera PE, Morgiel E, et al. Systemic sclerosis without antinuclear antibodies or Raynauds phenomenon: a multicenter study in the prospective EULAR Scleroderma Trials and Research (EUSTAR) database. Rheumatology (Oxford) 2013;52:560-7.

Hamaguchi Y, Hasegawa M, Fujimoto M, Matsushita T, Komura K, Kaji K, et al. The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. Br J Dermatol 2008;158:487-95.

Walker JG, Fritzler MJ. Update on autoantibodies in systemic sclerosis. Curr Opin Rheumatol 2007;19:580-91.

Admou B, Arji N, Seghrouchni F, Missoum H, El Fenniri L, Amghar S, et al. Low prevalence of anti-centromere antibodies in scleroderma in Morocco (about 272 cases). Ann Biol Clin (Paris) 2007;65(3):291-7.

Giddon AE, Dore CJ, Dunphy J, Betteridge Z, McHugh NJ, Paddison PJ, et al. Antinuclear antibodies and clinical associations in a British cohort with limited cutaneous systemic sclerosis. J Rheumatol 2011;38:702-5.

Meyer OC, Fertig N, Lucas M, Somogyi N, Medsger TA. Disease subsets, antinuclear antibody profile and clinical features in 127 French and 247 US adult patients with systemic sclerosis. J Rheumatol 2007;34:104-9.

Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma. Clin Rev Allergy Immunol 2012;43:249-55.

Müller CS, Paiva ES, Azevedo VF, Radominski SC, Lima FilhoJHC. Perfil de autoanticorpos e correlac¸ão clínica em umgrupo de pacientes com esclerose sistêmica na região Sul doBrasil. Rev Bras Reumatol 2011;51:319-24.

van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-55.

Hamaguchi Y. Autoantibody profiles in systemic sclerosis:predictive value for clinical evaluation and prognosis. J Dermatol 2010;37:42-53.

Horimoto AMC, da Costa IP. Antibodies in systemic sclerosis and their clinical correlation in patients from a midwestern region of Brazil. Rev Bras Rheumatol 2015;55:229-39.

Mehra S, Walker J, Patterson K, Fritzler MJ. Autoantibodies in systemic sclerosis. Autoimmun Rev 2013;12:340-54.

Behmanesh F, Amin R, Khajedaluee M, Fritzler MJ. Antibody profile in systemic sclerosis. Acta Medica Iranica 2010;48:12-20.

Nihtyanova SI, Denton CP. Autoantibodies as predictive tools in systemic sclerosis. Nature Rev Rheumatol 2010;6:112-6.

Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13:R211.

Vanthuyne M, Smith V, De Langhe E, Praet JV, Arat S, Depresseux G, et al. The Belgian systemic sclerosis cohort: correlations between disease severity scores, cutaneous subsets, and autoantibody profile. J Rheumatol 2012;39:2127-33.

Fritsch S, Pizzol VID, Paiva ES, Muller CS. Autoantibodies coexistence in systemic sclerosis: how to interpret it. Rev Bras Rheumatol 2012;52:949-55.


  • There are currently no refbacks.

ISSN: 1560-9014